Global Investment Platform Says "ShinlaGen's Finances Stable"... Positive Signal for Corporate Value Reappraisal

690 Billion Won in Cash and Debt-Free Management
Establishing an Independent Revenue Base Through WooSung Pharm Merger

ShinlaGen has secured a stable revenue base by incorporating WooSung Pharm into its pharmaceutical business through a merger and acquisition (M&A), and it has also secured sufficient cash reserves to continue research and development (R&D) over the medium and long term. The company has successfully established a virtuous cycle in which revenue from pharmaceutical sales leads to expanded R&D investment and clinical trials, moving away from a previous business structure that relied solely on new drug development achievements.

According to industry sources on September 15, the global investment information platform 'Simply Wall St' recently released a report evaluating ShinlaGen's cash burn rate and financial stability, stating that both remain at a stable level.

According to the report, ShinlaGen currently has approximately 6.9 billion won in cash and cash equivalents, and is operating debt-free. When considering its cash holdings relative to the net cash burn, ShinlaGen appears to have the financial capacity to stably continue its drug development without the need for additional external funding. In addition, the annual cash burn rate as a proportion of ShinlaGen's market capitalization is low, suggesting that the company also has ample room to procure funds through favorable means such as issuing mezzanine instruments or attracting strategic investors.

Last year, ShinlaGen completed its merger with WooSung Pharm, officially incorporating pharmaceuticals such as infusion and injectable products into its business, resulting in sales of 9.2 billion won, up 135% from the previous year. The company reduced its share of less related businesses such as commerce and expanded revenue centered on pharmaceutical sales, establishing a structure that allows it to offset losses from drug development with internal profits. ShinlaGen plans to continue diversifying its revenue sources in the future by acquiring product licenses and conducting joint research on improved drugs.

The completion of ShinlaGen’s virtuous business cycle is attributed to the fundamental strengthening enabled by support from its parent company, M2N. Previously experiencing financial uncertainties, ShinlaGen resolved its financial risks after becoming a subsidiary of M2N Group—which possesses financial affiliates such as Leadcorp and Mason Capital—by leveraging the parent company's stable capital base. Thanks to this support, ShinlaGen successfully proceeded with the incorporation of pharmaceutical businesses, including the acquisition of WooSung Pharm, providing a foundation for maximizing its clinical and R&D momentum globally.

Results from the company’s core pipeline clinical trials are also being realized. Its next-generation oncolytic virus platform 'SJ-600' series has not only been granted patents in major countries, but has also been published in leading international journals following extensive research. In addition, its first-in-class oncology candidate, 'BAL0891,' was recently designated as an orphan drug for acute myeloid leukemia (AML) by the United States Food and Drug Administration (FDA). Having moved away from a risk structure overly concentrated on the single pipeline ‘Pexa-Vec,’ ShinlaGen is now regarded as being fully prepared for a company value reappraisal, with strengthened capital from its parent company, its own revenue streams, and a diversified pipeline.

A ShinlaGen representative stated, “Based on our stable business structure and financial capacity, we have minimized new drug development risks and secured R&D continuity,” adding, “We will work to maximize corporate value by delivering visible achievements from our core pipeline.”

This content was produced with the assistance of AI translation services.